Use of body composition measurements to guide the assessment of dry weight in anuric dialysis patients: improvements in blood pressure control

GuoCun Hou\textsuperscript{a}, Hua Gan\textsuperscript{b,}\textsuperscript{*}, Xiuli Sun\textsuperscript{b}, Jing Li\textsuperscript{b}

\textsuperscript{a} Chongqing Medical University, Chongqing 400016, China
\textsuperscript{b} BaoTou Central Hospital Blood Purification Center, BaoTou 014040, China

\textbf{A R T I C L E  I N F O}

\textbf{Keywords:}
Body composition monitor
Post-dialysis overhydration
Maintenance hemodialysis
Pre-dialysis Blood pressure

\textbf{A B S T R A C T}

\textbf{Purpose:} Fluid management using a body composition monitor (BCM) based on bioimpedance spectroscopy has been found to be beneficial for maintenance hemodialysis (MHD) patients. Our purpose was to provide a management procedure for the adjustment of post-dialysis overhydration (OH\textsubscript{post}) and to evaluate whether this approach could improve blood pressure.

\textbf{Methods:} Post-dialysis fluid status was assessed weekly using the BCM. The reference value of OH\textsubscript{post} and the flow procedure for post-dialysis target weight (PDTW) adjustment were established via measurements of OH\textsubscript{post} in 60 normotensive MHD patients. In the interventional study, we adjusted the PDTW of hypertensive patients to the optimal OH\textsubscript{post} range, with a 0.2–0.5 kg change in PDTW per week.

\textbf{Results:} This observational study included 130 anuric MHD patients, of whom 60 were in the pre-dialysis systolic blood pressure (sBP\textsubscript{pre}) < 140 mmHg group. On multivariate logistic regression analysis, we found that only OH\textsubscript{post} was significantly associated with sBP\textsubscript{pre} < 140 mmHg (odds ratio = 2.293, \(p = 0.000\)). Patients in the OH\textsubscript{post} < −1.8 L group were mainly male and younger, and had higher post-dialysis diastolic blood pressure, ultrafiltration volume, levels of nutrition markers (serum albumin and creatinine), body mass index, and lean tissue index (LTI). On multiple stepwise regression analysis, only the change in LTI was found to be an independent predictor of OH\textsubscript{post} (\(R^2 = 0.208, \beta = −0.196, 95\% \text{ CI} (−0.296, −0.095), p < 0.001\)). The reference value of OH\textsubscript{post} was found to deviate by −2.5–0.5 L from that of normotensive patients. At the end of the study, the systolic blood pressure of 38 patients was less than 140 mmHg after PDTW adjustment. The changes in OH\textsubscript{post} from the initial to last adjustment were significant (\(t = 5.431, p < 0.001\)), with a substantial decrease in the sBP\textsubscript{pre} (\(t = 11.208, p < 0.001\)).

\textbf{Conclusions:} Assessment of OH\textsubscript{post} and LTI using a BCM with a patient-specific optimal PDTW adjustment flow can lead to significantly better control of hypertension in anuric MHD patients.

1. Introduction

Overhydration and hypertension are the most common complications in end-stage renal disease (ESRD) patients and are linked to increased mortality [1,2]. Fluid status is regarded to be the most important factor predisposing dialysis patients to hypertension or hypotension [3]. Many studies have shown that healthy blood pressure levels can be achieved in a large majority of patients, without using anti-hypertensive medication, by avoiding excess extracellular water through accurate fluid status assessment [4,5].

Clinical evaluation of fluid overload can be difficult in maintenance hemodialysis (MHD) patients and is prone to underestimation or overestimation [6,7]. Various objective methods have been recommended for defining fluid overload, such as measuring the inferior vena cava diameter, evaluation of N-terminal pro brain natriuretic peptide, lung ultrasonography, and use of a body composition monitor based on bioimpedance spectroscopy (BCM-BIS) [8–13]. The BCM (Fresenius Medical Care, Bad Homburg, Germany) is perhaps the best validated device in defining fluid status, with good overall agreement with the gold-standard isotope dilution techniques [14,15].

Some randomized controlled studies and observational studies have shown that BCM-BIS can help to establish an optimal post-dialysis target weight (PDTW) and obtain better clinical outcomes [16–21]. However, the best reference range for OH has still not been agreed universally. There may be differences in OH levels among ethnic groups, and OH levels may be affected by the time of measurement (pre- or post-dialysis) and diet (especially sodium intake) [22].

The aim of this study was to establish the optimal target values for...
post-dialysis overhydration (OH_{post}) in anuric MHD normotensive patients, and to provide a management procedure for the adjustment of PDTW, to evaluate whether this approach could improve blood pressure.

2. Materials and methods

2.1. Subjects

This observational study was performed at the dialysis unit of the BaoTou Central Hospital, Inner Mongolia, China, between October 2017 and January 2018. All patients who were treated for at least 3 months using regular hemodialysis (HD) were included, after obtaining their written informed consent. The study was approved by the institutional ethics committee of the BaoTou Central Hospital. The participants were clinically stable. The following patients were excluded from the study: 1) those aged < 18 years; 2) those with mechanical valves, pacemakers, coronary artery stents or implanted metallic devices; 3) those with hypotension and cramping in the last six intradialysis sessions; 4) those with daily urine ≥ 200 mL.

2.2. Body composition measurements

In all patients, the assessment of body composition was carried out weekly using the BCM. The measurements were performed approximately 20 min after the mid- or end-week HD session. Regarding the quality of measurements, a numerical indicator was displayed on the same screen as the Cole-Cole plot during measurements; a quality value close to 100% (usually ≥ 90%) and a smooth dome shape for the Cole-Cole plot indicated a successful measurement. BCM measurements were performed at baseline for all subjects.

The parameters obtained using the BCM were over-hydration (OH), total body water, intracellular water (ICW), extracellular water (ECW), ECW to ICW ratio (E/I), fat tissue index (FTI), and lean tissue index (LTI).

2.3. Clinical information

A patient questionnaire documenting sociodemographic status, personal and family health history, dialysis prescription, and medication for hypertension was completed by each patient, with the aid of doctors or nurses. Blood samples for standard laboratory parameters were obtained before the HD session. To improve the reproducibility of the blood pressure measurements, pre-dialytic systolic blood pressure (sBP_{pre}) recordings of six previous dialysis sessions were averaged.

2.4. The observational study

OH_{post} was the main parameter used for PDTW adjustment in the current study. The study flow diagram is shown in Fig. 1. In the observational study, through retrospective analysis of the normotensive group of patients, we obtained a reference value for OH_{post}. OH_{post} was combined with LTI to obtain the optimal PDTW adjustment protocol.

2.5. The intervention study

In the intervention study, 70 hypertensive MHD patients participated in the study, all of whom were anuric. In accordance with the flow procedure for PDTW adjustment, we adjusted PDTW to the optimal OH_{post} range, with a 0.2–0.5 kg change in PDTW per week. During the period of weight reduction, antihypertensive medication was continually reviewed and progressively reduced where possible.

2.6. Statistical methods

Patient characteristics were summarized using standard descriptive statistics. Categorical variables were presented as frequencies and percentages and continuous variables as mean ± standard deviation or as median and interquartile ranges, as appropriate. Baseline differences between normotensive and hypertensive patients were evaluated using an independent samples t-test for continuous variables and chi-square tests for categorical variables. Multivariate analysis was performed when differences in variables were significant in the univariate analysis. Comparison between variables was performed through one-way ANOVA in different categorical groups (grouped by OH_{post} data), and post hoc analysis was performed using the Bonferroni test. Correlations were also established between the OH_{post} and the variables using the Spearman rho test. Intragroup comparisons were performed using a paired t-test.

All statistical tests were performed using the Statistical Package for the Social Sciences 20.0 software. Statistical significance was defined as p < 0.05.

3. Results

3.1. Basic demographic data

There were 75 males (57.692%) and 55 females (42.308%) enrolled in this study. The patient baseline characteristics are shown in Table 1.

3.2. Comparison between the groups

We compared the different clinical parameters and body composition parameters in patient groups with different systolic blood pressures before dialysis (sBP_{pre} < 140 mmHg and sBP_{pre} ≥ 140 mmHg). The results are summarized in Table 2. Except for lower antihypertensive medication (AHT), lower OH_{post}, and lower E/I ratio in the sBP_{pre} < 140 mmHg group, no clinical and body composition parameters were different between the sBP_{pre} < 140 mmHg group and the sBP_{pre} ≥ 140 mmHg group.

Multivariate logistic regression analysis based on OH_{post}, E/I ratio, and E/W parameters showed that only OH_{post} was significantly associated with sBP_{pre} ≥ 140 mmHg (odds ratio (OR) = 2.293, p = 0.000).

---

Fig. 1. Study flow diagram.
Table 1
Baseline characteristics of the patients.

| Parameter                  | n = 130                     |
|----------------------------|-----------------------------|
| Age (y)                    | 56.100 ± 12.872             |
| Gender [male/female, n (%)]| 75 (57.692%) / 55 (42.308%)|
| Etiology, n (%)            |                             |
| Chronic glomerulonephritis | 27 (20.769)                 |
| Diabetic nephropathy       | 34 (26.154)                 |
| Hypertensive nephropathy   | 34 (26.154)                 |
| Polycystic kidney disease  | 5 (3.846)                   |
| Lupus or vasculitis        | 6 (4.615)                   |
| Chronic interstitial nephritis | 5 (3.846)                   |
| Other                      | 3 (2.308)                   |
| Undetermined               | 16 (12.308)                 |
| Hemodialysis vintage (mo)  | 41.631 ± 29.372             |

Table 2
Patient clinical parameters and body composition differences between groups.

|                       | Grouped by systolic blood pressure before dialysis (n = 130) | t or χ² | p       | Beta Exp | p       |
|-----------------------|-------------------------------------------------------------|---------|---------|----------|---------|
| sBPpre < 140 mmHg     |                                                        |         |         |          |         |
| sBPpre ≥ 140 mmHg     |                                                        |         |         |          |         |
| Age (y)               | 55.233 ± 13.642                                             | −0.664  | 0.508   |          |         |
| Sex (f/m)             | 27/33                                                       | 0.331   | 0.565   |          |         |
| Vintage (mo)          | 40.450 ± 31.272                                             | −0.348  | 0.729   |          |         |
| Diabetes mellitus (%) | 17 (28.333%)                                               | 0.274   | 0.601   |          |         |
| Ultrafiltration volume (mL) | 2354.167 ± 781.963                               | −0.233  | 0.816   |          |         |
| AHT                   | 0.793 ± 0.993                                               | −4.064  | 0.000   |          |         |
| Hemoglobin (g/L)      | 121.867 ± 15.546                                            | 1.025   | 0.307   |          |         |
| Creatinine (mmol/L)   | 918.983 ± 263.320                                           | 0.913   | 0.363   |          |         |
| Serum albumin (g/L)   | 40.885 ± 3.128                                              | −0.663  | 0.508   |          |         |
| Na⁺ (mmol/L)          | 139.450 ± 3.321                                             | 1.602   | 0.112   |          |         |
| Body mass index       | 23.303 ± 3.668                                              | 0.754   | 0.452   |          |         |
| OHpost (L)            | −0.958 ± 1.160                                              | −4.776  | 0.000   | 2.293    | 0.000   |
| Total body water (L)  | 27.812 ± 5.672                                              | −0.291  | 0.772   |          |         |
| Extracellular water (L) | 12.253 ± 2.195                      | −1.666  | 0.098   | 1.069    | 0.458   |
| Intracellular water (L) | 15.558 ± 3.779                        | 1.209   | 0.229   |          |         |
| E/Ti                  | 0.806 ± 0.118                                               | −3.238  | 0.002   | 0.278    | 0.596   |
| Lean tissue index (kg/m²) | 11.392 ± 2.702                | 0.223   | 0.824   |          |         |
| Fat tissue index (kg/m²) | 12.180 ± 4.385                    | 0.906   | 0.366   |          |         |

3.4. Flow procedure for PDTW adjustment protocol

In accordance with the above results, OHpost and LTI were the main parameters used for post-dialysis target weight (PDTW) adjustment. The reference value for OHpost was determined by excluding values lower than the 10th percentile and higher than the 90th percentile for data collected from normotensive patients, yielding −2.5 L and 0.5 L, respectively. LTI data in the sBPpre < 140 mmHg group were normally distributed with a mean of 11.392 ± 2.702 kg/m². The normal distribution of the LTI in this cohort is summarized in Table 3. We chose the 50th percentile (LTI = 11.1 kg/m² and OHpost = −1.0 L) as the cut-off value for the PDTW adjustment protocol. A flow diagram showing the PDTW adjustment procedure is provided in Fig. 2. When patients have symptomatic hypotension and severe cramps, the adjustment must be stopped whether or not the blood pressure is normal.

3.5. Interventional study in sBPpre ≥ 140 mmHg patients

The adjustment flow procedure of the interventional study is depicted in Fig. 2. Of the 70 hypertensive patients who underwent PDTW adjustments, four were excluded from further analysis because of a lack of follow-up (n = 3) or death (n = 1), leaving a total of 66 patients in the interventional study cohort. Of these, the systolic blood pressure of 38 patients (57%) was less than 140 mmHg after PDTW adjustment (Fig. 3). The changes in OHpost from the initial to last adjustment were significant (t = 5.431, p < 0.001), with a substantial decrease in the sBPpre (t = 11.208, p < 0.001). Consequently, the systolic blood pressure of 28 patients (43%) did not reach the normotensive level after PDTW adjustment. The changes in OHpost and sBPpre from the initial to last adjustment failed to reach statistical significance (t = 1.820, p = 0.080; t = 1.162, p = 0.255). Twelve patients had intradialytic symptoms in the last study week (eight patients suffered cramps, two suffered hypertensive episodes, one suffered cold sweating, and one suffered hoarseness). Of these, five patients (including two hypertensive patients and three patients who experienced cramps) were in the blood pressure target achievement group, and seven were in the blood pressure target non-achievement group.

4. Discussion

Among the factors causing hypertension in MHD patients, overhydration is thought to be the most important [23–25]. Dry weight is
more important in anuric MHD patients. Persistent hypervolemia causes hypertension and congestive heart failure, and leads to higher mortality. At present, there is no objective gold standard method to estimate target dry weight, and clinical assessment is unreliable. Recently, a meta-analysis reported that bioimpedance analysis-based interventions for the correction of overhydration improved systolic blood pressure control in end-stage kidney disease [26]. Moissl et al. reported that every 1 L change in fluid overload was accompanied by a 9.9 mmHg/L change in pre-dialysis systolic blood pressure [21]. In the current study, we found that only OHpost was significantly associated with sBPpre ≥ 140 mmHg (OR = 2.293, p = 0.000). OHpost was one of most important and potentially adjustable causes of hypertension in MHD patients.

Although detailed BCM-based dry weight adjustment protocols have been previously published, there is still no uniform reference range for OH [16, 18, 21, 27]. There are multiple reasons for the discrepancies in the target range, including different BCM measuring times, different ethnic groups and subjects, ages, sodium intake, variations in daily urine volume, and different body compositions. To minimize the effects of these factors, we selected subjects with daily urine < 200 mL and without hypotension or cramping during the last six intra-dialysis sessions. Chen et al. provided a simple and applicable algorithm for PDTW adjustment with BCM-BIS. The only shortcoming was that OHpost was the only parameter in the algorithm, and the range of reference values was derived from MHD patients generally [18]. Our clinical experience of volume assessment, and found that a strict dry-weight adjustment protocol (Fig. 2).

Table 3 Summary statistics of OHpost and LTI in 60 normal systolic blood pressure patients.

| Variable                      | Mean ± SD | Range | 5th pctl | 10th pctl | 25th pctl | 50th pctl | 75th pctl | 90th pctl | 95th pctl |
|-------------------------------|-----------|-------|----------|-----------|-----------|-----------|-----------|-----------|-----------|
| OHpost (L)                    | −0.958 ± 1.160 | − 3.100 to −2.900 | − 2.595 | − 2.490 | − 1.800 | − 0.950 | − 0.250 | 0.490 | 1.085 |
| LTI (kg/m²)                   | 11.392 ± 2.702 | 5.900 to 17.200 | 16.980 | 15.530 | 13.000 | 11.100 | 9.725 | 7.900 | 6.835 |

Table 4 The relationship between clinical parameters and hydration status in the sBPpre < 140 mmHg group.

| OHpost group (n = 60) | < −1.8 L | −1.8 to −0.25 L | > −0.25 L |
|-----------------------|---------|-----------------|-----------|
| Age (yr)              | 41.214 ± 9.023 * # | 59.065 ± 10.930 | 60.400 ± 13.968 |
| Sex (m/f)             | 12/23 | 14/17 | 7/7 |
| Vintage (mo)          | 30.500 ± 18.245 | 47.000 ± 20.987 | 45.600 ± 46.394 |
| Diabetes mellitus (%) | 1/14 | 10/31 | 6/15 |
| sBPpost (mmHg)        | 130.500 ± 7.133 | 128.387 ± 9.711 | 128.333 ± 9.217 |
| dBPpost (mmHg)        | 81.214 ± 5.899 b | 74.581 ± 7.932 | 70.400 ± 12.894 |
| Antihypertensive medication | 1.071 ± 0.997 | 0.710 ± 1.071 | 0.667 ± 0.817 |
| Ultrafiltration volume (L) | 2846.286 ± 874.077 | 2295.161 ± 618.918 | 2000.000 ± 802.674 |
| serum albumin (g/L)    | 42.686 ± 3.321 c | 40.756 ± 2.368 | 39.453 ± 3.672 |
| Creatinine (mmol/L)    | 118.500 ± 177.341 | 883.548 ± 230.276 | 742.533 ± 264.133 |
| Hemoglobin (g/L)       | 117.929 ± 14.248 | 124.032 ± 13.870 | 121.067 ± 19.779 |
| Body mass index (kg/m²) | 24.457 ± 3.499 d | 23.884 ± 3.471 d | 21.027 ± 3.449 |
| Lean tissue index (kg/m²) | 13.914 ± 2.089 a | 11.084 ± 2.344 | 9.673 ± 2.281 |
| Fat tissue index (kg/m²) | 11.400 ± 4.731 | 11.316 ± 3.467 | 10.973 ± 3.907 |

*: < −1.8 L Vs −1.8 − −0.25 L, P < 0.001; #, < −1.8 L Vs −0.25 L, P = 0.000.
#: < −1.8 L Vs −0.25 L, P = 0.006.
#: < −1.8 L Vs −1.8 − −0.25 L, P = 0.001; II, < −1.8 L Vs −0.25 L, P = 0.000.
$: < −1.8 L Vs −0.25 L, P = 0.014.
$: < −1.8 L Vs −1.8 − −0.25 L, P < 0.001; γ, < −1.8 L Vs −0.25 L, P = 0.000.
$: < −1.8 L Vs −0.25 L, P = 0.017.
$: < −1.8 L Vs −0.25 L, P = 0.030; δ, −1.8 − −0.25 L Vs −0.25 L, P = 0.034.
$: p = 0.031.
patients with cramps, one patient with hypotensive episodes). However, these complications did not result in hospitalization or other adverse outcomes. Although the systolic blood pressure of 28 patients (43%) did not reach the normotensive level after PDTW adjustment, more than 75% of patients showed a systolic blood pressure of under 160 mmHg. The changes in OH\textsubscript{post} and sBP\textsubscript{pre} from the initial to last adjustment failed to reach statistical significance (\(t = 1.820, p = 0.080\); \(t = 1.162, p = 0.255\)). There are several factors to be considered in this context. First, nine patients were not willing to decrease their PDTW, although the BCM clearly indicated overhydration. Second, the OH\textsubscript{post} of 19 patients was in the reference range, but their blood pressure was above normotensive level. Some studies have also reported that a small subgroup of dialysis patients demonstrate a state of normohydration but have an elevated mean systolic BP. It was not possible to control hypertension through fluid removal because of hypotension and ischemia [25]. In the current study, we also observed that adverse effects were more common in these patients (five patients suffered cramps, one suffered cold sweating, and one suffered hoarseness). It remains to be demonstrated whether improved control of blood pressure in these patients is possible by following different management strategies.

There were limitations to this study. First, the present study was conducted in one medical center and included a relatively small number of patients. Patients were not randomized into control and intervention groups, and the accuracy of the management strategy for OH\textsubscript{post} adjustment in hypertension patients requires further study. A second limitation is that the study had a short follow-up period. Charra et al. reported a lag phenomenon in blood pressure control in dialysis patients [30]. Our results showed that OH\textsubscript{post} reduction was associated with an improvement in blood pressure in 57% of patients, and that it might be possible in the future to increase the percentage if a longer follow-up period was used. Third, there was no examination of sleep apnea, renal artery stenosis, primary aldosteronism or pheochromocytoma in our patient exclusion criteria, which may have an impact on the results.

In conclusion, this is one of the first prospective studies to detect the optimal OH\textsubscript{post} target in anuric MHD patients. This study provided an effective and applicable management strategy for PDTW that can either normalize blood pressure or make hypertension easier to control in the great majority of anuric MHD patients. It considers differences in body composition (LTI), which makes this management strategy safer and more patient-specific than previous approaches.
Acknowledgements

The work was funded by the Baotou Science and Technology Bureau (ID:2018C2007-02-15, China).

Appendix A. Transparency document

Supplementary data associated with this article can be found in the online version at doi:10.1016/j.bbrep.2019.01.005.

References

[1] V. Wizemann, P. Wabel, P. Chamney, et al., The mortality risk of overhydration in haemodialysis patients, Nephrol. Dial. Transplant. 24 (2009) 1574–1579.

[2] S.D. Hwang, J.H. Lee, S.W. Lee, J.K. Kim, M.J. Kim, J.H. Song, Risk of overhydration and low lean tissue index as measured using a body composition monitor in patients on haemodialysis: a systemic review and meta-analysis, Ren. Fail. 40 (2018) 51–59.

[3] P.W. Chamney, M. Krämer, C. Rode, W. Kleinekofort, V. Wizemann, A new technique for establishing dry weight in haemodialysis patients via whole body bioimpedance, Kidney Int. 61 (2002) 2250–2258.

[4] C. Chazot, P. Wabel, P. Chamney, U. Moissl, S. Wieskotten, V. Wizemann, Importance of normohydration for the long-term survival of haemodialysis patients, Nephrol. Dial. Transplant. 27 (2012) 2404–2410.

[5] B. Charra, E. Calemard, M. Cuche, G. Laurent, Control of hypertension and prolonged survival on maintenance haemodialysis, Nephron 53 (1989) 96–99.

[6] R. Agarwal, Hyperension and survival in chronic hemodialysis patients-past lessons and future opportunities, Kidney Int. 67 (2005) 1–13.

[7] C.W. McIntyre, J.O. Burton, N.M. Selby, et al., Hemodialysis-guided fluid management and cardiovascular events, J. Cardiovasc. Imaging 32 (2016) 263–270.

[8] B. Vujicić, I. Mikolasević, S. Racki, L. Orlić, D. Ljutić, I. Bubić, BCM-body composition monitor: a new tool for the assessment of volume-dependent hypertension in patients on maintenance haemodialysis, Coll. Antropol. 37 (2013) 815–819.

[9] D.F. Keane, P. Baxter, E. Lindley, et al., The body composition monitor: a flexible tool for routine fluid management across the haemodialysis population, Biomed. Phys. Eng. Express 3 (2017) 035017.

[10] M. Onofreescu, S. Hogas, L. Voroneanu, et al., Bioimpedance-guided fluid management in maintenance haemodialysis: a pilot randomized controlled trial, Am. J. Kidney Dis. 64 (2014) 111–118.

[11] E. Hir, M. Usta, H. Toz, et al., Effect of fluid management guided by bioimpedance spectroscopy on cardiovascular parameters in haemodialysis patients: a randomized controlled trial, Am. J. Kidney Dis. 61 (2013) 957–965.

[12] C. Huan-Sheng, C. Yeong-Chang, H. Ming-Hsing, et al., Application of bioimpedance spectroscopy in Asian dialysis patients (ABISAD-III): a randomized controlled trial for clinical outcomes, Int. Urol. Nephrol. 48 (2016) 1897–1909.

[13] U.M. Mozaffarian, B-type natriuretic peptide is not a volume marker among patients on haemodialysis, Nephrol. Dial. Transplant. 28 (2013) 3082–3089.

[14] R.M. Moissl, P. Wabel, P.W. Chamney, et al., Body fluid volume determination via body composition spectroscopy in health and disease, Physiol. Meas. 27 (2006) 921–933.

[15] J.G. Rainmann, F. Zhu, J. Wang, et al., Comparison of fluid volume estimates in chronic hemodialysis patients by bioimpedance, direct isotopic, and dilution methods, Kidney Int. 85 (2014) 898–908.

[16] M. Onofreescu, S. Hogas, L. Voroneanu, et al., Bioimpedance-guided fluid management in maintenance haemodialysis: a pilot randomized controlled trial, Am. J. Kidney Dis. 64 (2014) 111–118.

[17] H.S. Chen, K.C. Lee, C.T. Cheng, et al., Application of bioimpedance spectroscopy in Asian dialysis patients (ABISAD): serial follow-up and dry weight evaluation, Clin. Kidney J. 6 (2013) 29–34.

[18] U. Moissl, M. Arias-Guillén, P. Wabel, et al., Bioimpedance-guided fluid management in hemodialysis patients, Clin. Am. Soc. Nephrol. 8 (2013) 1575–1582.

[19] H. Nakagawa, Y. Sato, H. Toshimori, S. Fujimoto, Evaluation of a new bio-impedance spectroscopy device in healthy Japanese, Biomed. Mater. Eng. 26 (2016) 97–102.

[20] J. Wilson, T. Shah, A.R. Nissenson, Role of sodium and volume in the pathogenesis of hypertension in hemodialysis, Semin. Dial. 17 (2004) 260–264.

[21] R.L. Lim, M. Elseviers, P. Rogiers, et al., Importance of volume factors in dialysis related hypertension, Clin. Nephrol. 48 (1997) 29–33.

[22] P. Wabel, U. Moissl, P. Chamney, et al., Towards improved cardiovascular management: the necessity of combining blood pressure and fluid overload, Nephrol. Dial. Transplant. 23 (2008) 2965–2971.

[23] A. Govic, A.I. Giumangel, D. Sirinpol, et al., Value of bioimpedance analysis estimated “dry weight” in maintenance dialysis patients: a systematic review and meta-analysis, Int. Urol. Nephrol. 49 (2017) 2231–2245.

[24] P. Machek, T. Jirka, U. Moissl, P. Chamney, P. Wabel, Guided optimization of fluid status in haemodialysis patients, Nephrol. Dial. Transplant. 25 (2010) 538–544.

[25] R. Agarwal, P. Alborzi, S. Satyan, R.P. Light, Dry-weight reduction in hypertensive hemodialysis patients (DRIP): a randomized, controlled trial, Hypertension 53 (2009) 500–507.

[26] G. Caratola, D. Bollignano, S. Rastelli, et al., Ultratfiltration intensification in hemodialysis patients improves hypertension but increases AV fistula complications and cardiovascular events, J. Nephrol. 24 (2011) 465–473.

[27] B. Charra, J. Bergström, B.H. Scribner, Blood pressure control in dialysis patients: importance of the lag phenomenon, Am. J. Kidney Dis. 32 (1998) 720–724.